Assessment of folate receptor alpha and beta expression in selection of lung and pancreatic cancer patients for receptor targeted therapies

Jiayin Shen, Yingwen Hu, Karson S. Putt, Sunil Singhal, Haiyong Han, Daniel W Visscher, Linda M. Murphy, Philip S. Low

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

A number of folate receptor (FR) targeted small molecular drugs and monoclonal antibodies have been introduced into clinical trials to treat FR positive cancers. Because the therapeutic efficacy of these drugs depends prominently on the level of FR-α expression on the cancer cells, patients have been commonly selected for FRtargeted therapies based on the intensity of a folate-targeted radioimaging agent. Unfortunately, uptake of such imaging agents can be mediated by both major isoforms of the folate receptor, FR-α and FR-β. Logically, if the FR positive cell population in a tumor mass is dominated by FR-β positive macrophages, patients could be selected for therapy that have few FR-expressing cancer cells. Although several IHC studies have examined expression of either FR-α or FR-β, no study to date has investigated expression of both FR-α and FR-β in the same tumor mass. Herein, we utilize monoclonal antibodies specific for FR-α (mAb343) and FR-β (m909) to query each isoform's expression in a range of cancers. We show that lung and pancreatic adenocarcinomas express the full spectrum of FR-α and FR-β combinations with ~76% of lung adenocarcinomas expressing both FR-α and FR-β while pancreatic cancers express primarily FR-β. Thus, while folate-targeted imaging of lung cancer patients might accurately reflect the expression of FR-α on lung cancer cells, imaging of pancreatic cancer patients could mislead a physician into treating a nonresponding patient. Overall, these data suggest that an independent analysis of both FR-α and FR-β should be obtained to predict the potential efficacy of a folate-targeted drug.

Original languageEnglish (US)
Pages (from-to)4485-4495
Number of pages11
JournalOncotarget
Volume9
Issue number4
DOIs
StatePublished - Jan 1 2018

Fingerprint

Folate Receptor 2
Folate Receptor 1
Pancreatic Neoplasms
Folic Acid
Lung Neoplasms
Therapeutics
Neoplasms

Keywords

  • Folate receptor alpha
  • Folate receptor beta
  • Lung cancer
  • Pancreatic cancer
  • Tumor associated macrophages

ASJC Scopus subject areas

  • Oncology

Cite this

Assessment of folate receptor alpha and beta expression in selection of lung and pancreatic cancer patients for receptor targeted therapies. / Shen, Jiayin; Hu, Yingwen; Putt, Karson S.; Singhal, Sunil; Han, Haiyong; Visscher, Daniel W; Murphy, Linda M.; Low, Philip S.

In: Oncotarget, Vol. 9, No. 4, 01.01.2018, p. 4485-4495.

Research output: Contribution to journalArticle

Shen, Jiayin ; Hu, Yingwen ; Putt, Karson S. ; Singhal, Sunil ; Han, Haiyong ; Visscher, Daniel W ; Murphy, Linda M. ; Low, Philip S. / Assessment of folate receptor alpha and beta expression in selection of lung and pancreatic cancer patients for receptor targeted therapies. In: Oncotarget. 2018 ; Vol. 9, No. 4. pp. 4485-4495.
@article{e7ad1d0cd41746e6bc870bf0b424e608,
title = "Assessment of folate receptor alpha and beta expression in selection of lung and pancreatic cancer patients for receptor targeted therapies",
abstract = "A number of folate receptor (FR) targeted small molecular drugs and monoclonal antibodies have been introduced into clinical trials to treat FR positive cancers. Because the therapeutic efficacy of these drugs depends prominently on the level of FR-α expression on the cancer cells, patients have been commonly selected for FRtargeted therapies based on the intensity of a folate-targeted radioimaging agent. Unfortunately, uptake of such imaging agents can be mediated by both major isoforms of the folate receptor, FR-α and FR-β. Logically, if the FR positive cell population in a tumor mass is dominated by FR-β positive macrophages, patients could be selected for therapy that have few FR-expressing cancer cells. Although several IHC studies have examined expression of either FR-α or FR-β, no study to date has investigated expression of both FR-α and FR-β in the same tumor mass. Herein, we utilize monoclonal antibodies specific for FR-α (mAb343) and FR-β (m909) to query each isoform's expression in a range of cancers. We show that lung and pancreatic adenocarcinomas express the full spectrum of FR-α and FR-β combinations with ~76{\%} of lung adenocarcinomas expressing both FR-α and FR-β while pancreatic cancers express primarily FR-β. Thus, while folate-targeted imaging of lung cancer patients might accurately reflect the expression of FR-α on lung cancer cells, imaging of pancreatic cancer patients could mislead a physician into treating a nonresponding patient. Overall, these data suggest that an independent analysis of both FR-α and FR-β should be obtained to predict the potential efficacy of a folate-targeted drug.",
keywords = "Folate receptor alpha, Folate receptor beta, Lung cancer, Pancreatic cancer, Tumor associated macrophages",
author = "Jiayin Shen and Yingwen Hu and Putt, {Karson S.} and Sunil Singhal and Haiyong Han and Visscher, {Daniel W} and Murphy, {Linda M.} and Low, {Philip S.}",
year = "2018",
month = "1",
day = "1",
doi = "10.18632/oncotarget.23321",
language = "English (US)",
volume = "9",
pages = "4485--4495",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "4",

}

TY - JOUR

T1 - Assessment of folate receptor alpha and beta expression in selection of lung and pancreatic cancer patients for receptor targeted therapies

AU - Shen, Jiayin

AU - Hu, Yingwen

AU - Putt, Karson S.

AU - Singhal, Sunil

AU - Han, Haiyong

AU - Visscher, Daniel W

AU - Murphy, Linda M.

AU - Low, Philip S.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - A number of folate receptor (FR) targeted small molecular drugs and monoclonal antibodies have been introduced into clinical trials to treat FR positive cancers. Because the therapeutic efficacy of these drugs depends prominently on the level of FR-α expression on the cancer cells, patients have been commonly selected for FRtargeted therapies based on the intensity of a folate-targeted radioimaging agent. Unfortunately, uptake of such imaging agents can be mediated by both major isoforms of the folate receptor, FR-α and FR-β. Logically, if the FR positive cell population in a tumor mass is dominated by FR-β positive macrophages, patients could be selected for therapy that have few FR-expressing cancer cells. Although several IHC studies have examined expression of either FR-α or FR-β, no study to date has investigated expression of both FR-α and FR-β in the same tumor mass. Herein, we utilize monoclonal antibodies specific for FR-α (mAb343) and FR-β (m909) to query each isoform's expression in a range of cancers. We show that lung and pancreatic adenocarcinomas express the full spectrum of FR-α and FR-β combinations with ~76% of lung adenocarcinomas expressing both FR-α and FR-β while pancreatic cancers express primarily FR-β. Thus, while folate-targeted imaging of lung cancer patients might accurately reflect the expression of FR-α on lung cancer cells, imaging of pancreatic cancer patients could mislead a physician into treating a nonresponding patient. Overall, these data suggest that an independent analysis of both FR-α and FR-β should be obtained to predict the potential efficacy of a folate-targeted drug.

AB - A number of folate receptor (FR) targeted small molecular drugs and monoclonal antibodies have been introduced into clinical trials to treat FR positive cancers. Because the therapeutic efficacy of these drugs depends prominently on the level of FR-α expression on the cancer cells, patients have been commonly selected for FRtargeted therapies based on the intensity of a folate-targeted radioimaging agent. Unfortunately, uptake of such imaging agents can be mediated by both major isoforms of the folate receptor, FR-α and FR-β. Logically, if the FR positive cell population in a tumor mass is dominated by FR-β positive macrophages, patients could be selected for therapy that have few FR-expressing cancer cells. Although several IHC studies have examined expression of either FR-α or FR-β, no study to date has investigated expression of both FR-α and FR-β in the same tumor mass. Herein, we utilize monoclonal antibodies specific for FR-α (mAb343) and FR-β (m909) to query each isoform's expression in a range of cancers. We show that lung and pancreatic adenocarcinomas express the full spectrum of FR-α and FR-β combinations with ~76% of lung adenocarcinomas expressing both FR-α and FR-β while pancreatic cancers express primarily FR-β. Thus, while folate-targeted imaging of lung cancer patients might accurately reflect the expression of FR-α on lung cancer cells, imaging of pancreatic cancer patients could mislead a physician into treating a nonresponding patient. Overall, these data suggest that an independent analysis of both FR-α and FR-β should be obtained to predict the potential efficacy of a folate-targeted drug.

KW - Folate receptor alpha

KW - Folate receptor beta

KW - Lung cancer

KW - Pancreatic cancer

KW - Tumor associated macrophages

UR - http://www.scopus.com/inward/record.url?scp=85040452480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040452480&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.23321

DO - 10.18632/oncotarget.23321

M3 - Article

AN - SCOPUS:85040452480

VL - 9

SP - 4485

EP - 4495

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 4

ER -